Skip to main content
SpringerLink
Log in

Cardiac transplantation and other therapeutic options in the treatment of end-stage heart disease

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

This article focuses on the surgical treatment of heart failure. It reviews the advances and limitations of heart transplantation and gives a broad overview of emerging technologies in the treatment of end-stage heart disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. ISHLT Registry Data Base, 1999. International Society for Heart and Lung Transplantation, 435 N. Michigan Ave., STE 1717, Chicago, IL 60611.

  2. Hunt SA, Gamberg P, Stinson EB, et al. The Stanford experience: survival and renal function in the pre-Sandimmune era compared to the Sandimmune era. Transplant Proc. 1990;22(Suppl 1):1–5.

    PubMed  CAS  Google Scholar 

  3. Constanzo-Nordin MR, Grady KL, Johnson MR, et al. Long-term effects of cyclosporin-based immunosuppression in cardiac transplantation: the Loyola experience. Transplant Proc. 1990;22(Suppl 1):6–11.

    Google Scholar 

  4. Mercer P, Sharples L, Edmunds J, et al. Evaluating the donor pool: impact of using hearts from donors over the age of 49 years. Transplant Proc. 1997;29:3293–3296.

    Article  PubMed  CAS  Google Scholar 

  5. Stevenson LW, Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant. 1991;10: 468–476.

    PubMed  CAS  Google Scholar 

  6. Miller LW. Outpatient dobutamine for refractory congestive heart failure: advantages, techniques, and results. J Heart Lung Transplant. 1991;10:482–87.

    PubMed  CAS  Google Scholar 

  7. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338(3):161–165.

    Article  PubMed  CAS  Google Scholar 

  8. Isobe M, Suzuki J, Yamazaki S, et al., Regulation by differential development of Th-1 and Th-2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation. 1997;96(7):2247–2253.

    PubMed  CAS  Google Scholar 

  9. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000;342:613–619.

    Article  PubMed  CAS  Google Scholar 

  10. Pucci AM, Forbes RD, Billingham ME. Pathologic features in long-term cardiac allografts. J Heart Transplant. 1990(9): 339–345.

    PubMed  CAS  Google Scholar 

  11. Southworth MR, Mauro VF. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients. Ann Pharmacother. 1997;31(4): 489–491.

    PubMed  CAS  Google Scholar 

  12. Argenziano M, Oz MC, Rose EA, The continuing evolution of mechanical ventricular assistance. Curr Prob Surg. 1997; 34(4):317–386.

    CAS  Google Scholar 

  13. DeRose JJ, Argenziano M, Rose EA, et al. Implantable left ventricular assist devices: an evolving long-term cardiac replacement therapy. Ann Surg. 1997;226(4):461–470.

    Article  PubMed  CAS  Google Scholar 

  14. Reemtsma K, McCracken BH, Schlegel JU, Pearl M. Hetero-transplantation of the kidney: two clinical experiences. Science. 1964;(143):700–705.

    Article  PubMed  CAS  Google Scholar 

  15. Minanov OP, Itescu S, Michler RE. Recent advances and the potential for clinical use of xenotransplantation. Curr Opin Cardiol. 1996;11(2):214–220.

    Article  PubMed  CAS  Google Scholar 

  16. Rose EA, Pepino P, Fuzest L, et al. Cardiac xenotransplantation. Prog Cardiovasc Dis. 1990;33:105–117.

    Article  PubMed  CAS  Google Scholar 

  17. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med. 1987;316:297–303.

    Article  PubMed  CAS  Google Scholar 

  18. Milano A, Pratali S, Tartarini G, et al. Early results of transmyocardial revascularization with a holmium laser. Ann Thoracic Surg. 1998;65:700–704.

    Article  CAS  Google Scholar 

  19. Zlotnick AY, Ahmad RM, Reul RM, et al. Neovascularization occurs at the site of closed laser channels after transmyocardial laser revascularization. Surg Forum. 1996;47:286–287.

    Google Scholar 

  20. Bocchi EA, Bellotti G, Vilella de Moraes A, et al. Clinical outcome after left ventricular surgical remodeling in patients with idiopathic dilated cardiomyopathy referred for heart transplantation: short-term results. Circulation. 1997; 96:165–172.

    Google Scholar 

  21. Magovern CJ, Mack CA, Zhang J, et al. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther. 1997;8(2):215–227.

    PubMed  CAS  Google Scholar 

  22. Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in ischemic porcine heart. J Thoracic Cardiovasc Surg. 1998;115(1):168–177.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiac Transplantation, Columbia-Presbyterian Medical Center, 7-435 MHB, 177 Fort Washington Ave., 10032, New York, NY

    Robert Dabol MD & Niloo M. Edwards MD (Director)

Authors
  1. Robert Dabol MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niloo M. Edwards MD
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Dabol, R., Edwards, N.M. Cardiac transplantation and other therapeutic options in the treatment of end-stage heart disease. Compr Ther 26, 109–113 (2000). https://doi.org/10.1007/s12019-000-0020-y

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-000-0020-y

Keywords

Search

Navigation